The company's low growth and lack of profits have led to a stock price drop. A revenue growth acceleration might boost the share price. However, the real benefit for shareholders will be if the company starts making profits. Despite recent gains, the returns over the last three years have been disappointing.
DENTSPLY SIRONA's decreasing capital employment and flat returns are concerning. The stock's decline may reflect investor pessimism about these trends. The analysis does not see the traits of a multi-bagger in this stock.
Investors predict limited future growth for the company, reflected by its low P/S ratio. The pessimism around its revenue prospect contributes to its undervalued stock.
DENTSPLY SIRONA, currently undervalued with steady price trends, could make a solid investment. Despite modest growth projections, aspects like capital structure and management track record could be behind its undervaluation.
The reversal of DENTSPLY SIRONA's stock downward trend might hinge on its profitability. Accelerated revenue growth could yield share price bounce. However, present indications show a 4% annual shareholder loss over five years.
There is concern over the falling ROCE and constant capital utilization, pointing towards a likely state of stagnation for the business. Unless there is an improvement in these areas, this stock might not be the best investment option.
登士柏股票討論區
2023Q1營收增長1%,營業利潤下滑43%,淨利潤繼續虧損,目前看不到投資價值。
專欄Today's Pre-Market Stock Movers: QCOM, BA, ROKU, AZN and More
In reaction to earnings/guidance:
• $CalAmp(CAMP.US)$ +0.6%
Other news:
• $Cano Health(CANO.US)$ +6.1% ($哈門那(HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept醫療(CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial(LPLA.US)$ +4.1% (reports monthly activity for August)
• $登士柏(XRAY.US)$ +3% (names new CFO)
• $iPATH 標普500 VIX短期期貨ETN(VXX.US)$ +2.9% (tr...
專欄Today's pre-market stock movers: CHWY, PATH, SNAP, HPE and more
• $Repare Therapeutics(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US)$ +10.2% (In reaction ...
暫無評論